Suppr超能文献

游离DNA中谷胱甘肽-S-转移酶1基因启动子甲基化作为前列腺癌的诊断和预后工具:一项系统评价和荟萃分析

Glutathione-S-Transferase 1 Gene Promoter Methylation in Cell-Free DNA as a Diagnostic and Prognostic Tool for Prostate Cancer: A Systematic Review and Meta-Analysis.

作者信息

Ye Jinghe, Wu Mao, He Long, Chen Peng, Liu Hongtao, Yang Hongwei

机构信息

Department of Graduate School, China Medical University, Shenyang, China.

Department of Organ Transplantation Center, General Hospital of Northern Theatre Command, Shenyang, China.

出版信息

Int J Endocrinol. 2023 Jan 28;2023:7279243. doi: 10.1155/2023/7279243. eCollection 2023.

Abstract

BACKGROUND

Promoter methylation of glutathione-S-transferase 1 (GSTP1) is related to the occurrence of prostate cancer (PCa), but reports are inconsistent about the accuracy of GSTP1 promoter methylation in PCa diagnosis and prognosis. Therefore, we systematically evaluated the diagnostic and prognostic value of GSTP1 promoter methylation in PCa.

METHODS

The PubMed, EMBASE, Web of Science, and PMC databases were searched for all relevant studies from the date of inception to November 31, 2021. We compared differences in the incidence of GSTP1 promoter methylation in cfDNA between prostate cancer patients and controls. The odds ratio (OR) and hazard ratio (HR) were used as effect sizes, and the result of each effect size is expressed as a 95% confidence interval (95% CI).

RESULTS

Our meta-analysis showed that the combined sensitivity and specificity of GSTP1 promoter methylation in cfDNA for the diagnosis of prostate cancer were 0.37 (95% CI = 0.23, 0.53) and 0.97 (95% CI = 0.88, 0.99), respectively. The area under the curve (AUC) with 95% CI was 0.78 (95% CI = 0.75, 0.82). For prognostic variables, hypermethylation of GSTP1 was associated with shorter survival in PCa (HR = 2.57, 95% CI = 1.30, 5.10), with statistical significance in between-study heterogeneity (  = 72%, =0.006). The results of the subgroup analysis indicated that the heterogeneity of studies may be due to differences in the observed indicators.

CONCLUSIONS

The results of the meta-analysis substantiate the high specificity of promoter methylation of GSTP1 in cfDNA for the diagnosis of prostate cancer, and it may be used to more precisely evaluate the prognosis of patients with prostate cancer. It may be helpful for the early detection of prostate cancer, but it still must be combined with traditional prostate-specific antigen (PSA) or other methylated genes to accomplish this goal.

摘要

背景

谷胱甘肽 - S - 转移酶1(GSTP1)启动子甲基化与前列腺癌(PCa)的发生有关,但关于GSTP1启动子甲基化在PCa诊断和预后中的准确性报道并不一致。因此,我们系统评估了GSTP1启动子甲基化在PCa中的诊断和预后价值。

方法

检索PubMed、EMBASE、Web of Science和PMC数据库,查找从数据库建立至2021年11月31日的所有相关研究。我们比较了前列腺癌患者和对照组中循环游离DNA(cfDNA)中GSTP1启动子甲基化发生率的差异。比值比(OR)和风险比(HR)用作效应量,每个效应量的结果以95%置信区间(95%CI)表示。

结果

我们的荟萃分析表明,cfDNA中GSTP1启动子甲基化用于诊断前列腺癌的合并敏感性和特异性分别为0.37(95%CI = 0.23,0.53)和0.97(95%CI = 0.88,0.99)。曲线下面积(AUC)及其95%CI为0.78(95%CI = 0.75,0.82)。对于预后变量,GSTP1高甲基化与PCa患者较短生存期相关(HR = 2.57,95%CI = 1.30,5.10),研究间异质性具有统计学意义(I² = 72%,P = 0.006)。亚组分析结果表明,研究的异质性可能归因于观察指标的差异。

结论

荟萃分析结果证实cfDNA中GSTP1启动子甲基化在诊断前列腺癌方面具有高特异性,并且它可用于更精确地评估前列腺癌患者的预后。它可能有助于前列腺癌的早期检测,但仍必须与传统的前列腺特异性抗原(PSA)或其他甲基化基因联合使用才能实现这一目标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e15/9899149/26bae54bd29d/IJE2023-7279243.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验